MNPR vs. EDSA, MBRX, PTI, DARE, CNSP, CELU, LTRN, RLYB, RMTI, and THTX
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Proteostasis Therapeutics (PTI), Daré Bioscience (DARE), CNS Pharmaceuticals (CNSP), Celularity (CELU), Lantern Pharma (LTRN), Rallybio (RLYB), Rockwell Medical (RMTI), and Theratechnologies (THTX). These companies are all part of the "medical" sector.
Monopar Therapeutics (NASDAQ:MNPR) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Monopar Therapeutics received 14 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 75.76% of users gave Edesa Biotech an outperform vote while only 70.91% of users gave Monopar Therapeutics an outperform vote.
Monopar Therapeutics has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Monopar Therapeutics presently has a consensus price target of $2.00, indicating a potential upside of 146.61%. Edesa Biotech has a consensus price target of $39.00, indicating a potential upside of 749.67%. Given Edesa Biotech's higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Monopar Therapeutics.
Monopar Therapeutics' return on equity of -110.42% beat Edesa Biotech's return on equity.
1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Monopar Therapeutics had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 2 mentions for Monopar Therapeutics and 0 mentions for Edesa Biotech. Monopar Therapeutics' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.
Summary
Monopar Therapeutics beats Edesa Biotech on 6 of the 10 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
